Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jaktinib in Myelofibrosis (Phase II, China, Single-arm)
CTR20180453Phase 2Completed
- Sponsor
- Suzhou Zelgen Biopharmaceuticals
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of jaktinib in myelofibrosis (MF), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), sponsored by Suzhou Zelgen Biopharmaceuticals. Started Apr 2018; status: completed.
02
Drugs
jaktinib
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)
Beyond the preview
Go deeper on CTR20180453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180453.